00:00We are at the ESMO Congress in Barcelona, the most important oncology congress in Europe and one of the most important in the world.
00:08We have just witnessed the publication and presentation of the results updated four years ago of the NATALI study.
00:17What is the NATALI study?
00:18It is a study that has predicted the addition of a new drug to hormone therapy,
00:24the standard treatment that we have been doing for years for women with breast cancer.
00:31Ribociclib, which is the dose of two compresses a day for three years,
00:36added to hormone therapy has produced further improvement in the risk of these patients,
00:41reducing the risk of the disease, the so-called recidivism, by about 28.5%.
00:49It even reaches 34.4% in women at a lower risk, that is, those without metastasis and lymph nodes.
00:57What is the good news?
00:59The good news is that now these results are very mature and stable,
01:04therefore directly transferable in clinical practice as soon as the drug is available,
01:09and since there is a tendency to improve with the maturation of the data,
01:14it is possible that they will mature, improving further in the coming years.
01:18So it is really good news for women with breast-operated hormone-sensitive tumors,
01:25because the foundations are laid for an improvement of the recovery rates.
